investing.comNov 11$AZTA

Azenta Q4 2026 slides: 11.6% EBITDA margin, 3-5% growth ahead

Azenta Life Sciences (AZTA) reported Q4 2026 earnings of $0.28 per share on $167M revenue, beating estimates. Full-year revenue was $622M with adjusted EBITDA margin at 9.4%. The company guided for 3-5% organic growth in 2027 and margin expansion. Shares rose 16.35% post-earnings.

Original reporting

investing.com

Published Nov 11, 2026, 2:49 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 11, 2026, 3:03 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$AZTA

Bullish

high confidence

Mentioned

$AZTA

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$AZTABullishHigh

Why it matters

The earnings beat and guidance lift sentiment, supporting a bullish short‑term outlook.

Market read

Strong earnings and guidance drive immediate price appreciation and may influence peer valuations in the biotech services space.

What to watch

Potential headwinds from legacy Sanger sequencing decline and capital spending in Q1 may temper near‑term cash flow.

Relevance 8/10Novelty 8/10Timing: today after earnings release

Background

Azenta Life Sciences (NASDAQ:AZTA) announced Q4 2026 results with earnings beat, margin expansion, and FY2027 guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AZTABullishHigh confidence

Context

Azenta reported Q4 2026 earnings beat and raised FY2027 guidance, causing a 16.35% share surge.

Expected impact

upward pressure as investors price in stronger margins and growth guidance

Evidence & confidence

Earnings beat, margin expansion, cash generation and share buyback signal financial strength; guidance above consensus drives bullish sentiment.

Market effects

Sector

Life‑sciences and genomics services sector may see broader optimism from Azenta's results.

Regional

U.S. biotech and tech‑focused investors likely benefit from the surprise.

Global

Limited to investors tracking U.S. biotech equities.

Counterpoint

What could challenge this read

If margin expansion stalls or integration costs of recent acquisitions rise, the stock could face downside.

Key entities

company
Azenta Life Sciences
Provider of sample management and genomic services.

Read at source ← All news

$AZTAHigh

Why Azenta Stock Crushed it on Wednesday

Azenta (AZTA) stock surged 21% after reporting Q4 2026 revenue of $167M, up 5% YoY, and adjusted earnings of $0.28 per share, exceeding estimates. The company guided FY2027 revenue to $648M-$660M with margin expansion. Azenta focuses on automated sample storage for healthcare.

finance.yahoo.comNov 12

$AZTAHigh

Azenta (AZTA) Q4 2026 Earnings Call Transcript

Azenta (AZTA) reported Q4 2026 revenue slightly better than expected, with double-digit growth in Sample Repository Services and Consumables & Instruments. The company aims for profitable revenue growth in 2027, with initiatives in commercial expansion and new product launches. Fiscal 2026 saw 2% organic revenue growth and an adjusted EBITDA margin of 9.4%.

finance.yahoo.comNov 11

$KRMDMedAI 8/10

Biotech And Healthcare Stocks Move Higher: KRMD, CARL Surge 24%, AZTA Climbs 23%

Biotech and healthcare stocks surged after strong quarterly results. KORU Medical (KRMD) reported 11.2% revenue growth, raising FY26 guidance. Carlsmed (CARL) saw 65% revenue growth, also raising guidance. Azenta (AZTA) reported 5% revenue growth and issued FY27 outlook. Capricor (CAPR) rose on FDA review progress for its DMD therapy.

rttnews.comNov 11

$AZTAMed

Jefferies raises Azenta stock price target on growth outlook

Jefferies raised Azenta's (AZTA) price target to $52 from $44, citing strong Q4 results and 2027 growth outlook. The stock trades at $49.42, up 126% in six months. AZTA reported non-GAAP EPS of $0.28 vs. $0.12 estimate and revenue of $167M vs. $160.32M estimate. The company plans investments in multiomics and has $500M in cash.

investing.comNov 11

$AZTAMedAI 8/10

What Azenta (AZTA) Said on Its Q4 Earnings Call

Azenta (AZTA) reported Q4 revenue growth of 9% in Sample Management Solutions and flat revenue in Multiomics. The company expects 3-4% organic revenue growth in Q1 and improved free cash flow by 25% in fiscal 2026. Automated Stores faced challenges but is expected to return to modest growth. Azenta made acquisitions in gene synthesis and plans restructuring for cost savings.